ESMO 2022 Conference Coverage


 

ESMO 2022: Early Decreases in KRAS Mutant Allele Frequency Predicts Clinical Benefit to the PLK1 Inhibitor Onvansertib in Combination With FOLFIRI/Bev in 2L Treatment of mCRC

47 views
September 27, 2022
0 Comments
Login to view comments. Click here to Login
GI